Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

The estrogen pathway as a modulator of response to immunotherapy.

Velez MA, Burns TF, Stabile LP.

Immunotherapy. 2019 Sep;11(13):1161-1176. doi: 10.2217/imt-2019-0024. Epub 2019 Jul 30.

PMID:
31361169
2.

SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.

Bossart EA, Tasdemir N, Sikora MJ, Bahreini A, Levine KM, Chen J, Basudan A, Jacobsen BM, Burns TF, Oesterreich S.

Breast Cancer Res Treat. 2019 Jun;175(2):327-337. doi: 10.1007/s10549-019-05161-8. Epub 2019 Feb 23.

PMID:
30798422
3.

TWIST1 regulation of circRNA: a novel mechanism to promote epithelial-mesenchymal transition in hepatocellular carcinoma.

Yochum ZA, Burns TF.

Noncoding RNA Investig. 2018 Dec;2. pii: 71. doi: 10.21037/ncri.2018.12.01. Epub 2018 Dec 19. No abstract available.

4.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK.

J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.

PMID:
30615550
5.

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.

Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, Rudin CM, Tran PT, Burns TF.

Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. Epub 2018 Aug 31.

6.

Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia.

Burns TF, Loo EY, Bengtson EM, Bao L.

Ann Hematol. 2019 Jan;98(1):211-213. doi: 10.1007/s00277-018-3399-1. Epub 2018 Jul 20. No abstract available.

PMID:
30030569
7.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

8.

HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC.

Han J, Goldstein LA, Hou W, Chatterjee S, Burns TF, Rabinowich H.

Autophagy. 2018;14(6):958-971. doi: 10.1080/15548627.2018.1434471. Epub 2018 Mar 21.

9.

Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.

Volonte D, Vyas AR, Chen C, Dacic S, Stabile LP, Kurland BF, Abberbock SR, Burns TF, Herman JG, Di YP, Galbiati F.

J Biol Chem. 2018 Feb 2;293(5):1794-1809. doi: 10.1074/jbc.M117.815902. Epub 2017 Dec 15.

10.

Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.

Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, Hu J.

Mol Cancer Ther. 2018 Apr;17(4):806-813. doi: 10.1158/1535-7163.MCT-17-0561. Epub 2017 Nov 22.

11.

First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC.

Ancevski Hunter K, Friedland DM, Villaruz LC, Burns TF.

J Thorac Oncol. 2018 Jan;13(1):e3-e5. doi: 10.1016/j.jtho.2017.09.1963. Epub 2017 Oct 5. No abstract available.

12.

Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.

Chatterjee S, Burns TF.

Int J Mol Sci. 2017 Sep 15;18(9). pii: E1978. doi: 10.3390/ijms18091978. Review.

13.

TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression.

Godse NR, Khan N, Yochum ZA, Gomez-Casal R, Kemp C, Shiwarski DJ, Seethala RS, Kulich S, Seshadri M, Burns TF, Duvvuri U.

Clin Cancer Res. 2017 Dec 1;23(23):7324-7332. doi: 10.1158/1078-0432.CCR-17-1561. Epub 2017 Sep 12.

14.

A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.

Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, Wang H, Attar MA, Huang EH, Chatley SN, Nugent K, Somasundaram A, Engh JA, Ewald AJ, Cho YJ, Rudin CM, Tran PT, Burns TF.

Mol Cancer Res. 2017 Dec;15(12):1764-1776. doi: 10.1158/1541-7786.MCR-17-0298. Epub 2017 Aug 29.

15.

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics.

Donnenberg VS, Mandic M, Rhee JC, Burns TF, Meibohm B, Korth-Bradley JM.

J Clin Pharmacol. 2017 Aug;57(8):947-955. doi: 10.1002/jcph.938. Epub 2017 Jun 14. Review.

PMID:
28614591
16.

Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC.

Chatterjee S, Huang EH, Christie I, Burns TF.

Mol Cancer Ther. 2017 Aug;16(8):1658-1668. doi: 10.1158/1535-7163.MCT-17-0114. Epub 2017 May 31.

17.

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.

18.

The next generation of immunotherapy: keeping lung cancer in check.

Somasundaram A, Burns TF.

J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5. Review.

19.

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.

Somasundaram A, Burns TF.

Lung Cancer (Auckl). 2017 Jan 11;8:1-11. doi: 10.2147/LCTT.S105678. eCollection 2017. Review.

20.

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.

Chatterjee S, Huang EH, Christie I, Kurland BF, Burns TF.

Mol Cancer Ther. 2017 May;16(5):793-804. doi: 10.1158/1535-7163.MCT-16-0677. Epub 2017 Feb 6.

21.

Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance.

Yochum ZA, Socinski MA, Burns TF.

J Thorac Dis. 2016 Nov;8(11):E1528-E1531. doi: 10.21037/jtd.2016.11.59. No abstract available.

22.

HSP90 inhibitors in lung cancer: promise still unfulfilled.

Chatterjee S, Bhattacharya S, Socinski MA, Burns TF.

Clin Adv Hematol Oncol. 2016 May;14(5):346-56. Review.

PMID:
27379696
23.

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.

Davar D, Socinski MA, Dacic S, Burns TF.

Exp Hematol Oncol. 2015 Dec 14;4:34. doi: 10.1186/s40164-015-0029-7. eCollection 2015.

24.

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.

Bhattacharya S, Socinski MA, Burns TF.

Clin Transl Med. 2015 Dec;4(1):35. doi: 10.1186/s40169-015-0075-0. Epub 2015 Dec 14.

25.

NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function.

Sun F, Qu Z, Xiao Y, Zhou J, Burns TF, Stabile LP, Siegfried JM, Xiao G.

Oncogene. 2016 May 5;35(18):2299-310. doi: 10.1038/onc.2015.299. Epub 2015 Aug 24.

26.

Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells.

Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, Wang H, Malek R, Taparra K, Cades J, Annadanam A, Yoon AR, Fertig E, Firulli BA, Mazzacurati L, Burns TF, Firulli AB, An SS, Tran PT.

Neoplasia. 2015 Jan;17(1):16-31. doi: 10.1016/j.neo.2014.10.009.

27.

Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Burns TF, Stabile LP.

Lung Cancer Manag. 2014 Feb 1;3(1):43-52.

28.

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

Somasundaram A, Socinski MA, Burns TF.

Expert Opin Pharmacother. 2014 Dec;15(18):2693-708. doi: 10.1517/14656566.2014.971013. Epub 2014 Nov 10. Review.

PMID:
25381900
29.

Do oncogenic drivers exist in squamous cell carcinoma of the lung?

Villaruz LC, Burns TF, Socinski MA.

Oncology (Williston Park). 2013 Sep;27(9):906, 913-4. No abstract available.

30.

Personalizing therapy in advanced non-small cell lung cancer.

Villaruz LC, Burns TF, Ramfidis VS, Socinski MA.

Semin Respir Crit Care Med. 2013 Dec;34(6):822-36. doi: 10.1055/s-0033-1358552. Epub 2013 Nov 20. Review.

31.

The twist box domain is required for Twist1-induced prostate cancer metastasis.

Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, Chung CH, Rudin CM, Herman JM, Hales RK, Raman V, An SS, Tran PT.

Mol Cancer Res. 2013 Nov;11(11):1387-400. doi: 10.1158/1541-7786.MCR-13-0218-T. Epub 2013 Aug 27.

32.

The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.

Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, Dacic S.

Cancer. 2013 Jun 15;119(12):2268-74. doi: 10.1002/cncr.28039. Epub 2013 Mar 22.

33.

Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.

Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, Aziz K, Cho YJ, Tran PT, Rudin CM.

Mol Cancer Res. 2013 Apr;11(4):329-38. doi: 10.1158/1541-7786.MCR-12-0456. Epub 2013 Jan 30.

34.

Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.

Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, Withofs N, Sweet-Cordero A, Gambhir SS, Rudin CM, Felsher DW.

PLoS Genet. 2012;8(5):e1002650. doi: 10.1371/journal.pgen.1002650. Epub 2012 May 24.

35.

Detection of circulating tumor cells in the cerebrospinal fluid: a new frontier.

Burns TF, Wolff AC.

Cell Cycle. 2012 Jan 15;11(2):203-4. doi: 10.4161/cc.11.2.18780. Epub 2012 Jan 15. No abstract available.

PMID:
22189717
36.

Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.

Burns TF, Juergens RA.

Oncology (Williston Park). 2010 Nov 30;24(13):1223-4, 1226. No abstract available.

37.

Lung cancer in 'never-smokers': beyond EGFR mutations and EGFR-TK inhibitors.

Burns TF, Rudin CM.

Oncology (Williston Park). 2010 Jan;24(1):48-9. Review. No abstract available.

38.

Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling.

Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W, El-Deiry WS.

Cancer Biol Ther. 2006 Oct;5(10):1408-14. Epub 2006 Oct 30.

39.

p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia.

Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS.

J Clin Endocrinol Metab. 2005 Jun;90(6):3568-74. Epub 2005 Mar 15.

40.

DR5 knockout mice are compromised in radiation-induced apoptosis.

Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T, El-Deiry WS.

Mol Cell Biol. 2005 Mar;25(5):2000-13.

41.

Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.

Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS.

Cancer Cell. 2004 Dec;6(6):597-609.

42.
43.

Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.

Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS.

Mol Cell Biol. 2003 Aug;23(16):5556-71.

44.

Cell death signaling in maligancy.

Burns TF, el-Deiry WS.

Cancer Treat Res. 2003;115:319-43. Review. No abstract available.

PMID:
12613203
45.
46.
47.
48.

Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest.

Wu GS, Burns TF, McDonald ER 3rd, Meng RD, Kao G, Muschel R, Yen T, el-Deiry WS.

Oncogene. 1999 Nov 11;18(47):6411-8.

49.

BRCA1 signals ARF-dependent stabilization and coactivation of p53.

Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH, Weber BL, el-Deiry WS.

Oncogene. 1999 Nov 11;18(47):6605-14.

50.

The p53 pathway and apoptosis.

Burns TF, El-Deiry WS.

J Cell Physiol. 1999 Nov;181(2):231-9. Review. No abstract available.

PMID:
10497302

Supplemental Content

Loading ...
Support Center